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Inhibition of immune checkpoints programmed death 1 (PD-1) and
cytotoxic T lymphocyte-associated protein 4 (CTLA-4) on T cells
results in durable antitumor activity in melanoma patients. Despite
high frequency of melanoma brain metastases (BrM) and associated
poor prognosis, the activity and mechanisms of immune checkpoint
inhibitors (ICI) in metastatic tumors that develop within the “im-
mune specialized” brain microenvironment, remain elusive. We
established a melanoma tumor transplantation model with intracra-
nial plus extracranial (subcutaneous) tumor, mimicking the clinically
observed coexistence of metastases inside and outside the brain.
Strikingly, intracranial ICI efficacy was observed only when extra-
cranial tumor was present. Extracranial tumor was also required for
ICI-induced increase in CD8+ T cells, macrophages, and microglia in
brain tumors, and for up-regulation of immune-regulatory genes.
Combined PD-1/CTLA-4 blockade had a superior intracranial efficacy
over the two monotherapies. Cell depletion studies revealed that
NK cells and CD8+ T cells were required for intracranial anti–PD-1/
anti–CTLA-4 efficacy. Rather than enhancing CD8+ T cell activation
and expansion within intracranial tumors, PD-1/CTLA-4 blockade
dramatically (∼14-fold) increased the trafficking of CD8+ T cells to
the brain. This was mainly through the peripheral expansion of
homing-competent effector CD8+ T cells and potentially further en-
hanced through up-regulation of T cell entry receptors intercellular
adhesion molecule 1 and vascular adhesion molecule 1 on tumor
vasculature. Our study indicates that extracranial activation/release
of CD8+ T cells from PD-1/CTLA-4 inhibition and potentiation of their
recruitment to the brain are paramount to the intracranial anti–PD-1/
anti–CTLA-4 activity, suggesting augmentation of these processes as
an immune therapy-enhancing strategy in metastatic brain cancer.
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Brain metastases (BrM) are an unmet clinical need with verylimited treatment options and poor prognosis. Metastatic
melanoma has the highest risk of spreading to the central ner-
vous system (CNS) among common cancers; up to a quarter of
patients have BrM at metastatic diagnosis, and the incidence at
autopsy is up to ∼75% (1–3). Until recently, treatment options
for melanoma BrM have been restricted to radiotherapy, sur-
gery, and targeted therapies, with the median overall survival
below 1 y (4, 5). In recent years, cancer treatment has been
revolutionized by immunotherapy targeting programmed death 1
(PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-
4) immune-inhibitory receptors (immune checkpoints) expressed
mainly on T cells. Function-blocking antibodies against CTLA-4
(ipilimumab) and PD-1 (nivolumab, pembrolizumab) enhance
antitumor T cell responses and result in durable antitumor ac-
tivity across most cancers (6, 7). In melanoma, the anti–PD-1/
anti–CTLA-4 combination therapy showed a superior efficacy
compared with the two monotherapies (8), and has been ap-
proved in various countries (9). Despite numerous studies on
anti–PD-1 and anti–CTLA-4 in melanoma, very limited data are
available for BrM, mainly due to frequent exclusion of patients
with BrM from clinical trials (4, 10). A handful of retrospective
and prospective clinical studies indicated activity of ipilimumab
in melanoma BrM with 16–25% intracranial response rate, but
also suggested that only a subgroup of patients is likely to benefit
(4, 5, 11). Pembrolizumab and nivolumab also showed efficacy in
melanoma BrM with an ∼21% response rate in the brain (12–15). A
very recent interim analyses from two clinical trials in drug treatment-
naïve patients with melanoma BrM [ABC trial (15) and CheckMate
204 trial (16)] reported a 50% and 55% intracranial response rate
following combined anti–PD-1 plus anti–CTLA-4 therapy.
In addition to limited clinical data, there is a complete lack of
preclinical data on anti–PD-1 and anti–CTLA-4 therapy in
melanoma BrM. Preclinical studies in BrM are hampered by the
lack of melanoma models that can recapitulate clinically ob-
served metastatic patterns and coexistence of metastases in dif-
ferent organs. Spontaneous metastasis to the brain in preclinical
models is a rare event and macroscopic BrM are usually not
observed (17). Only two immunocompetent preclinical mela-
noma models of spontaneous BrM have been reported (18, 19),
but analysis of BrM-specific survival in therapeutic studies
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remains a challenge due to a faster development of extracranial
compared with intracranial metastases.
Notably, differences in regulation of adaptive T cell responses
to antigens located in the CNS compared with antigens outside
the CNS have been well documented (20–24). Due to this dif-
ference in adaptive immune responses, the CNS has been re-
ferred to as “immune specialized.” Moreover, the phenotype of
immune cells infiltrating brain metastases has been shown to be
altered by inflammatory molecules up-regulated specifically in
cancer cells growing in the brain parenchyma (25). Hence, with
immune checkpoint inhibitors (ICI) now being frontline therapy
for metastatic melanoma, the question arises as to what extent
the metastatic tumors residing within the immune specialized
brain microenvironment respond to ICI. Moreover, the re-
quirements for effective anti–PD-1/anti–CTLA-4 therapy in the
brain remain to be identified.
To address the above knowledge gaps and study anti–PD-1/
anti–CTLA-4–dependent survival and mechanisms specifically in
BrM while simulating the clinically observed coexistence of
metastasis in the skin [the most common metastatic site (26)], we
established a melanoma transplantation model with extracranial
(subcutaneous) plus intracranial tumors, in which the overall
survival depends on the intracranial tumor growth. In addition to
demonstrating a superior intracranial efficacy of combined PD-1/
CTLA-4 blockade over the two monotherapies, we made a
striking observation that anti–PD-1/anti–CTLA-4 activity in the
brain depends on the presence of extracranial tumor, highlight-
ing the importance of mimicking clinically observed extracranial
disease in the context of ICI studies. We further show that the
intracranial activity of anti–PD-1/anti–CTLA-4 therapy requires
the augmentation of CD8+ T cell trafficking to the brain and we
analyze the underlying mechanisms.
Results
The Presence of Extracranial Tumor Is Critical for Intracranial Anti–
PD-1/Anti–CTLA-4 Efficacy. The vast majority of BrM in mela-
noma coincide with metastases outside the brain, predominantly
in the skin (26). To mimic this clinical situation, we established a
tumor transplantation model of B16 melanoma with extracranial
(subcutaneous) plus intracranial tumors. To identify the optimal
experimental timeline allowing us to study survival specifically in
dependence of intracranial tumor growth, we first determined
tumor growth kinetics and survival times in mice bearing either
extracranial or intracranial tumors (Fig. 1A and Fig. S1 A and B).
The mean survival time for mice with intracranial tumors was
10.8 ± 1.5 d. Extracranial tumors reached the maximum allowable
diameter of 15 mm on day 16.5 ± 1.4 and none of the mice showed
terminal symptoms at this time point. Thus, subcutaneous im-
plantation of cancer cells into the flank 3 d before their intracranial
implantation (Fig. 1B) allowed for quantification of the intracra-
nial tumor-dependent survival.
Following administration of four doses of either anti–CTLA-
4 or anti–PD-1 antibody monotherapy (Fig. 1B), the overall
survival of mice in this model was only marginally and non-
significantly extended compared with control mice receiving IgG
isotype antibody (Fig. 1C and Fig. S1C). In contrast to mono-
therapies, the anti–PD-1/anti–CTLA-4 combination significantly
prolonged survival in our model and inhibited intracranial as well
as extracranial tumor growth (Fig. 1 C–E and Fig. S1C). Thus,
the outcome of anti–PD-1/anti–CTLA-4 combination therapy
was superior to the two monotherapies, which is in line with the
reported clinical intracranial response rate for anti–PD-1 mono-
therapy (21–25%) (12–15) and anti–PD-1/anti–CTLA-4 combina-
tion therapy (50–55%) (15, 16), as well as the 6-mo progression-
free survival rate of 28% and 46%, respectively (15). Due to these
promising data, we focused on the anti–PD-1/anti–CTLA-4
combination therapy.
To validate the relevance of extracranial disease in the context
of anti–PD-1/anti–CTLA-4 therapy for BrM, we compared
therapeutic efficacy between mice bearing intracranial tumors
only [representing a conventional intracranial tumor trans-
plantation model (17, 27)], and mice bearing tumors at both
sites. Strikingly, in the absence of extracranial disease, the anti–
PD-1/anti–CTLA-4 combination failed to extend the survival or
to reduce the intracranial tumor burden (Fig. 1 F–H and Fig. S1
D and E). This observation reproduced in a B16 model over-
expressing an immunogenic ovalbumin (OVA) xenoantigen
(28), hence demonstrating that increasing the inherent im-
munogenicity of the model is not sufficient to induce antitu-
mor responses in the brain following PD-1/CTLA-4 blockade
(Fig. 1I). The requirement of extracranial disease for intracranial
anti–PD-1/anti–CTLA-4 efficacy was further confirmed in the
Ret melanoma model (19, 29), demonstrating that our findings
are model-independent (Fig. 1J; see Fig. S1 F–H for the es-
tablishment of experimental timeline in Ret model). Taken
together, our results reveal that the intracranial activity of anti–
PD-/anti–CTLA-4 depends on the extracranial tumor, high-
lighting the importance of including the clinically relevant
extracranial disease in this context.
Immune Response in the Brain Is Enhanced in the Presence of
Extracranial Disease. To evaluate the immunological response in
the brain upon anti–PD-1/anti–CTLA-4 therapy and the role of
extracranial disease, we analyzed the tumor-infiltrating immune
cells in intracranial B16 tumors by flow cytometry (Fig. S2A).
Although anti–PD-1/anti–CTLA-4 therapy resulted in a small
increase in intratumoral CD45+ cells in the absence of extra-
cranial disease, a major anti–PD-1/anti–CTLA-4–induced in-
crease in this cell population, and significant expansion of CD3+
T cells, were observed only in the presence of subcutaneous tu-
mor (Fig. 2 A–C and Fig. S2B). Similarly, anti–PD-1/anti–CTLA-
4–induced increases in CD8+ T cells (Fig. 2D), CD11b+F4/80+
CD45high (25, 30, 31) bone marrow-derived macrophages (Fig.
2G) and CD11b+F4/80+CD45low (25, 30, 31) brain-resident
microglia (Fig. 2H) were detected only in the presence of ex-
tracranial disease. In contrast, the percentages of total CD4+
T cells, FoxP3+CD4+ regulatory T cells (Treg) and FoxP3−CD4+
effector T cells (Teff) increased upon anti–PD-1/anti–CTLA-
4 treatment independent of extracranial tumor (Fig. 2D). The
CD4+Teff/Treg ratio, the increase of which was previously asso-
ciated with therapeutic efficacy in some studies (32), remained
unaltered (Fig. 2E). The proportion of NK cells also remained
unchanged (Fig. 2F). Importantly, similar changes in immune
cell populations within intracranial tumors were observed in the
Ret melanoma model (Fig. S3A).
To determine whether monotherapies are sufficient to in-
duce infiltration of immune cells into intracranial tumors, we
analyzed immune cell populations in mice bearing intracranial and
extracranial B16 tumors, following anti–PD-1 or anti–CTLA-
4 monotherapy. Both monotherapies failed to increase the pro-
portion of immune cells in intracranial tumors compared with
IgG-treated mice (Fig. S3B). Thus, the lack of therapeutic efficacy
observed for the two monotherapies was in line with their failure
to induce immune cell infiltration into intracranial tumors.
To evaluate the immunological response in the brain at the
molecular level, intracranial B16 tumors were profiled using
next-generation RNA sequencing (mRNAseq). Differential
gene-expression analysis (adjusted P < 0.05) indicated that the
presence of extracranial disease did not cause any significant
alterations in gene-expression levels in IgG-treated control
mice (Fig. 3A). In contrast, the presence of extracranial dis-
ease resulted in altered expression of 4,154 genes in anti–PD-
1/anti–CTLA-4–treated mice. This suggested that extracranial
disease has significant impact on the intracranial tumor only in the
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Fig. 1. Inhibition of intracranial tumor growth and prolonged survival following anti–PD-1/CTLA-4 therapy require the presence of extracranial disease.
(A) Survival of C57BL/6J mice following intracranial implantation of B16/Fluc melanoma cells (n = 8) and time to the establishment of extracranial B16 sub-
cutaneous tumors with a diameter of 15 mm (n = 10). (B) Experimental time line for the implantation of cancer cells in B16 model and therapeutic schedule. (C)
Survival of mice with intracranial (B16/Fluc) plus extracranial (B16) tumors following the administration of anti–PD-1, anti–CTLA-4, anti–PD-1/CTLA-4, or IgG control
(n = 8). The overall significance is shown. Individual P values are given in Fig. S1C. (D) Quantification of intracranial B16/Fluc tumor burden via bioluminescence
imaging (n = 20/24). Fold-change in bioluminescence signal intensity between days 12 and 5 (e.g., pre/posttreatment) for mice treated with anti–PD-1/CTLA-4 or
IgG. (E) Quantification of extracranial B16 tumor burden on day 12 via caliper measurement (n = 20/24). (F) Survival following anti–PD-1/anti–CTLA-4 or IgG
administration was compared between mice bearing only intracranial B16/Fluc tumors and mice bearing intracranial B16/Fluc and extracranial B16 tumors. The overall
significance is indicated. Individual P values are summarized in Fig. S1D. (G) Representative images of intracranial bioluminescence signals (B16/Fluc tumors). (H and I)
Fold-change in intracranial bioluminescence signal intensity between days 12 and 5 (e.g., pre/posttreatment) for the B16/Fluc (H) and B16/OVA/Fluc (I) melanomamodels
(n = 21/21/20/24 for B16/Fluc; n = 16/16/15/25 for B16/OVA/Fluc). Labeling as in F. (J) Quantification of intracranial Ret/Fluc melanoma burden (n = 8/8/8/13). Bio-
luminescence signal intensity (total flux; photons per second) is shown. Labeling as in F. Significant differences in C and Fwere determined with log-rank test. Significant
differences in D, E, and H–J were determined with a Mann–Whitney test (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001). Data from two (I) or three (C–F and H)
independent experiments are shown.

























context of PD-1/CTLA-4 blockade. By contrast, anti–PD-1/anti–
CTLA-4 therapy itself had impact on gene expression both in the
absence (906 differentially expressed genes) and presence
(621 differentially expressed genes) of extracranial disease. Im-
portantly, brain tumors from mice with intracranial and extra-
cranial tumors undergoing anti–PD-1/anti–CTLA-4 treatment
had significantly distinct transcriptomes compared with the other
three experimental groups (Fig. 3B). Gene ontology (GO) en-
richment analysis identified classes of genes significantly altered
upon anti–PD-1/anti–CTLA-4 therapy in the presence of extra-
cranial disease, revealing significant up-regulation in GO terms
relating to NK cell activation and chemotaxis (Fig. 3C), T cell
activation (Fig. 3D and Fig. S4A), and microglia/macrophage
activation and migration (Fig. 2E and Fig. S4B).
Hence, our data revealed that anti–PD-1/anti–CTLA-4 effi-
cacy in the brain correlates with intratumoral increase in CD8+
T cells, macrophages, and microglia, as well as up-regulation of
genes involved in activation of T cells, NK cells, and microglia/
macrophages. This implies that anti–PD-1/anti–CTLA-4 activity
relies on multiple immune cell populations, the activation or
intratumoral increase of which were dependent on the presence
of extracranial tumor.
CD8+ T Cells and NK Cells Are Required for the Intracranial Efficacy of
Anti–PD-1/Anti–CTLA-4 Therapy. The up-regulation of T cell and
NK cell activation markers in association with the intracranial
anti–PD-1/anti–CTLA-4 efficacy prompted us to investigate the
functional role of these cell populations in the context of PD-1/
CTLA-4 blockade. Antibody-mediated depletion of NK cells,
CD4+ or CD8+ T cells was performed in mice bearing in-
tracranial and extracranial B16 tumors undergoing anti–PD-1/
anti–CTLA-4 therapy (Fig. 4A). Efficient depletion of respective
Fig. 2. Analysis of immune cell populations in intracranial B16 tumors reveals extracranial tumor- and PD-1/CTLA-4 blockade-dependent changes.
(A) Representative dot plots of CD45+ cell population. (B) Representative immunofluorescence images of CD45+ cells infiltrating intracranial tumors.
(C) Percentages of CD45+ hematopoietic cells and CD3+ T cells as quantified by flow cytometry. Significant P values are summarized in Fig. S2B. (D–H) Analysis
of different T cell subpopulations (D), CD4+ Teff/Treg ratio (E ), NK cells (F ), CD11b
+F4/80+CD45high macrophages (G) and CD11b+F4/80+CD45low microglia
(H) within intracranial tumors by flow cytometry. Labeling as in D. All analyses were performed on day 12. Combined data from three independent
experiments are shown (n = 10/13/16/24 per group for CD45+, NK, microglia, and macrophages; n = 14/16/17/22 per group for T cell subpopulations).
Significant differences were determined by ANOVA with a post hoc test (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001). Detailed ANOVA pa-
rameters are provided in Table S1.
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cell populations in the blood and tumor tissue was confirmed by
flow cytometry (Fig. S5). While the depletion of CD4+ T cells had
no impact on survival (Fig. 4B), depletion of either NK (Fig. 4D) or
CD8+ T cells (Fig. 4C) resulted in a significant loss of survival
advantage observed upon anti–PD-1/anti–CTLA-4 therapy, dem-
onstrating a critical involvement of these cell populations.
To further characterize T cells in intracranial B16 tumors, we
analyzed the expression of known T cell activation/exhaustion
markers [e.g., CD25, CD69, Granzyme B, Eomesodermin (EOMES),
T-cell Ig, and mucin domain containing-3 (TIM3)] in CD4+ and
CD8+ T cells by flow cytometry (Fig. S6A). We detected no
changes in the percentages of cells expressing the investigated
markers or in their protein expression levels (mean fluores-
cence intensity, MFI) (Fig. S6 B and C). Therefore, marked
increase in the overall gene-expression levels of T cell activa-
tion markers following anti–PD-1/anti–CTLA-4 therapy in the
presence of extracranial tumor (Fig. 3D) can be explained by
the increased intratumoral percentage of CD8+ T cells (Fig.
2D). Our findings thus imply that inhibition of intracranial tu-
mor growth was caused by an increase in CD8+ T cell numbers
rather than their enhanced intratumoral activation.
Anti–PD-1/Anti–CTLA-4 Treatment Enhances Trafficking of CD8+ T
Cells to Intracranial Tumors. We next sought to determine the
underlying mechanism for the increase in intratumoral CD8+
T cells following anti–PD-1/anti–CTLA-4 therapy. The pro-
portion of proliferative CD8+ T cells within intracranial
B16 tumors was high (∼75% Ki67+ cells) and remained un-
affected by anti–PD-1/anti–CTLA-4 treatment or the presence
of extracranial disease (Fig. 5A). This finding excluded intra-
tumoral expansion of CD8+ T cells as a major driver of their intra-
tumoral increase. We therefore reasoned that enhanced recruitment
of CD8+ T cells from outside the brain is likely responsible for their
accumulation in intracranial tumors following PD-1/CTLA-4 block-
ade. To investigate this, we analyzed the trafficking of CD8+ T cells
to intracranial tumors by performing an adoptive transfer of Cell-
Trace Violet (CTV)-labeled CD8+ T cells (4 × 106) in mice with
extracranial plus intracranial tumors. T cell donor and recipient
mice both received two doses of anti–PD-1/anti–CTLA-4 or IgG
(Fig. 5B), which was sufficient to significantly increase the overall
percentage of intratumoral CD8+ T cells in treated compared with
control mice (Fig. S8A). CD8+ T cells from IgG-treated donor mice
were transferred into IgG-treated recipient mice, and cells from
anti–PD-1/anti–CTLA-4–treated donor mice were transferred into
anti–PD-1/anti–CTLA-4–treated recipient mice (Fig. 5B). Analysis
of intratumoral CTV+ CD8+ T cells at 18 h postadoptive transfer
demonstrated a strong increase (∼14-fold) in CD8+ T cell homing to
intracranial tumors in the presence of anti–PD-1/anti–CTLA-4
therapy (Fig. 5 C and D). Notably, we observed no significant pro-
liferation of adoptively transferred T cells within 18 h, and therefore
increase in intratumoral CTV+ CD8+ T cells was attributable ex-
clusively to their trafficking and not their proliferation (Fig. S8B).
To investigate whether systemic T cell expansion may con-
tribute to enhanced accumulation of CD8+ T cells in intracranial
B16 tumors, we analyzed peripheral T cell populations in the blood
and spleens. All anti–PD-1/anti–CTLA-4–dependent changes in
ratios of peripheral CD8+ T cells, CD4+ Teff, and Treg cells oc-
curred independently of extracranial disease (Fig. S7). In contrast,
PD-1/CTLA-4 blockade-induced increase in CD44+CD62L− effec-
tor CD8+ T cells in blood was significantly enhanced in the presence
Fig. 3. PD-1/CTLA-4 blockade- and extracranial disease-dependent molecular changes within intracranial B16 tumors. (A) Number of genes differentially
expressed within intracranial tumors between experimental groups. (B) Unsupervised hierarchical clustering and heat map of top 2,000 differentially
expressed genes. (C–E) Unsupervised hierarchical clustering and heat maps of differentially expressed genes involved in NK cell function (C; the list of genes is
based on the significantly enriched GO terms displayed on the Left), T cell function (D; example genes are shown; heat map including all genes is given in Fig.
S4B), and microglia (E). The analysis was performed on day 12.

























of extracranial disease, and thus correlated with the intracranial
anti–PD-1/anti–CTLA-4 efficacy (Fig. 5E). Analysis of in-
tracranial tumors revealed that the majority of intratumoral
CD8+ T cells were CD44+CD62L− effector cells in both treated
and control mice (Fig. 5F). This prompted us to compare homing of
CD44+CD62L− effector and CD44−CD62L+-naïve CD8+ T cells
to intracranial tumors. Notably, the percentage of CD8+ T cells
within pooled spleen and lymph nodes was slightly higher in
anti–PD-1/anti–CTLA-4–treated mice (10.3%) compared with
the IgG-treated mice (9%) (Fig. 5G, Upper). Moreover, the
percentage of CD44+CD62L− cells within CD8+ T cell pop-
ulation was higher in anti–PD-1/anti–CTLA-4–treated mice (3.8%)
compared with IgG-treated mice (2.2%) (Fig. 5G, Lower). Thus, to
ensure that the same numbers of cells per investigated CD8+ T cell
population are used for adoptive transfer in the control and ther-
apy group, we sorted CD44+CD62L− and CD44−CD62L+ CD8+
T cell populations from pooled spleens and lymph nodes of IgG-
and anti–PD-1/anti–CTLA-4–treated mice, respectively. CTV-
labeled CD44+CD62L− (1 × 105) and CD44−CD62L+ (2.4 × 106)
cells, respectively, were transferred into recipient mice that received
the corresponding treatment (Fig. 5B). Analysis of CTV+ CD8+
T cells within intracranial tumors at 18 h posttransfer confirmed
that only CD44+CD62L− cells efficiently homed to intracranial
tumors (Fig. 5H). Notably, we detected a tendency toward more
efficient homing of CD44+CD62L− CD8+ T cells isolated from
anti–PD-1/anti–CTLA-4–treated mice (0.009 ± 0.004% all
cells) compared with the IgG control mice (0.006 ± 0.002% all
cells) (Fig. 5I). In summary, this suggested that an enhanced
homing of CD8+ T cells to intracranial tumors following anti–
PD-1/anti–CTLA-4 therapy is mainly due to the peripheral ex-
pansion of CD44+CD62L− effector cells. However, a tendency to-
ward more efficient homing of effector CD8+ T cells isolated from
anti–PD-1/anti–CTLA-4–treated mice compared with IgG-treated
mice implied that additional factors may be involved.
PD-1/CTLA-4 Blockade Up-Regulates T Cell Trafficking Determinants
on Tumor Blood Vessels. Consistent with a tendency toward in-
creased trafficking of CD8+ effector T cells to intracranial tumors
following anti–PD-1/anti–CTLA-4 treatment, Kyoto Encyclopedia
of Genes and Genomes (KEGG) pathway analysis identified
“Leukocyte transendothelial migration” as one of the pathways
significantly up-regulated in intracranial tumors following PD-1/
CTLA-4 blockade in the presence of extracranial disease com-
pared with the other three experimental groups (Fig. 6A). Among
the up-regulated genes, vascular cell adhesion molecule 1 (Vcam1)
and intercellular adhesion molecule 1 (Icam1)—two major endo-
thelial T cell entry receptors (33)—were up-regulated 6.4- and 3.8-
fold, respectively (Fig. 6A). VCAM-1 expression on tumor blood
vessels was confirmed by immunofluorescence (Fig. 6B). Analysis
of VCAM-1 and ICAM-1 expression on tumor endothelial cells by
flow cytometry confirmed a significant up-regulation of both re-
ceptors following anti–PD-1/anti–CTLA-4 therapy in the presence
of extracranial disease (Fig. 6 C and D and Fig. S8C). The per-
centage of ICAM-1+ endothelial cells increased from ∼75 to 90%
and the percentage of VCAM-1+ endothelial cells from ∼5 to 45%.
Moreover, the expression levels of both receptors were ∼threefold
elevated, as indicated by a significant increase in MFI (Fig. 6D).
Following anti–PD-1/anti–CTLA-4 therapy, blood vessels
within the tumor-adjacent brain parenchyma remained negative
for VCAM-1 expression (Fig. S8D), indicating that the up-
regulation of T cell entry receptors was restricted to the tumor
microenvironment. In line with this finding, gene-expression
levels of Ifnγ, a known inducer of endothelial VCAM-1 and
ICAM-1 (33), were up-regulated within intracranial tumors fol-
lowing anti–PD-1/anti–CTLA-4 therapy in mice bearing tumors
at both sites (Fig. S8E). Concurrently, intracellular flow cytom-
etry staining revealed a significant increase in the percentage of
IFN-γ+ cells within NK cell and macrophage populations (Fig.
6E, Upper), while TNF-α expression remained unaltered (Fig.
S8F). Although such an increase in IFN-γ expression was not
detected for CD8+ T cells and microglia, their increased pro-
portion within intracranial tumors per se also contributed toward
an overall increase in IFN-γ (Fig. 6E, Lower).
In summary, our data indicate that anti–PD-1/anti–CTLA-
4 treatment—in the context of clinically relevant extracranial
disease—increases intratumoral CD8+ T cells in the brain through
Fig. 4. CD8+ T cells and NK cells are required for intracranial efficacy of PD-1/CTLA-4 blockade in B16 model. (A) Experimental timeline indicating admin-
istration of respective immune cell-depleting antibodies. (B–D) Survival analysis of anti–PD-1/anti–CTLA-4-treated mice bearing intracranial and extracranial
tumors following in vivo depletion of CD4+ T cells, CD8+ T cells, or NK cells, respectively (n = 16; pooled data from two independent experiments). Significant
differences were determined with log-rank test. P values shown are for comparison between the anti–PD-1/CTLA-4 group and the respective group in which a
specific immune cell population has been depleted; **P ≤ 0.01; ****P ≤ 0.0001.
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peripheral expansion of CD44+CD62L− effector CD8+ T cells
and potentiation of their trafficking to intracranial tumors, the
latter potentially occurring via up-regulation of T cell entry
receptors ICAM-1/VCAM-1 on the tumor vasculature.
Discussion
In this study, we reveal that extracranial disease plays a critical
role for the intracranial efficacy of combined anti–PD-1 plus
anti–CTLA-4 therapy. This was demonstrated through analysis
Fig. 5. Anti–PD-1/anti–CTLA-4 therapy in the context of extracranial disease potentiates trafficking of CD8+ T cells to intracranial B16 tumors. (A) Analysis of Ki67+
CD8+ T cells within intracranial tumors by flow cytometry. (B) Schematic representation of adoptive transfer experiments using CTV-labeled CD8+ T cells. (C)
Representative dot plot of adoptively transferred CTV+ CD8+ T cells detected within intracranial tumors. (D) Analysis of adoptively transferred CTV+ CD8+ T cells in
intracranial tumors at 18 h posttransfer (n = 10). Labeling as in A. (E and F) Analysis of CD44+CD62L− CD8+ effector T cells in blood (E) and intracranial tumors (F)
on day 12 (n = 6/6/7/12 for blood; n = 10/10 for intracranial tumors). Labeling as in A. (G) Dot plots of pooled spleen and lymph node cells isolated from donor mice
for use in adoptive CD8+ T cell transfer experiments. Percentages of total CD8+ T cells and CD44+CD62L− cells within the CD8+ T cell population are indicated. (H)
Representative dot plots of adoptively transferred CTV-tagged CD44+CD62L− (Upper) and CD44−CD62L+ (Lower) CD8+ T cells detected within intracranial tumors
at 18 h posttransfer. (I) Analysis of adoptively transferred CTV-tagged CD44+CD62L− CD8+ T cells in intracranial tumors at 18 h posttransfer (n = 5). Significant
differences in A and E were determined by ANOVA with a post hoc test, and in D, F, and I with a two-tailed t-test (unequal variance); **P ≤ 0.01; ****P ≤ 0.0001.
Data from at least two repeat experiments were pooled for analysis (A–F). Detailed ANOVA and t-test parameters are provided in Tables S1 and S2.

























of intracranial tumor-dependent survival, quantification of tu-
mor growth, characterization of tumor-infiltrating immune cell
populations, and gene-expression analysis (mRNAseq). Impor-
tantly, clinically observed intracranial activity of anti–PD-1/anti–
CTLA-4 therapy (4, 5, 11–15) could be recapitulated only in the
tumor transplantation model with intracranial plus extracranial
tumor, but not in the model bearing only intracranial cancer
lesions, which is a conventional brain tumor transplantation
model (17, 27). Moreover, superior intracranial activity of anti–
PD-1/anti–CTLA-4 combination therapy in our optimized model
was in line with the reported higher intracranial response rates with
combined anti–PD-1 plus anti–CTLA-4 (50%) than anti–PD-1 alone
Fig. 6. PD-1/CTLA-4 blockade up-regulates vascular T cell trafficking determinants in intracranial B16 tumors. (A) Unsupervised hierarchical clustering and
heat map of genes differentially expressed within the “Leukocyte transendothelial migration” KEGG pathway. FC, fold-change; pval, P value. (B) Immuno-
fluorescence staining for CD31 (endothelial cells) and VCAM-1 within intracranial tumors from treated mice bearing intracranial and extracranial tumors.
(C) Representative dot plots of endothelial cells (CD45−CD31+) and ICAM-1/VCAM-1 staining within the endothelial cell population. (D) Analysis of ICAM-1 and
VCAM-1 expression in intracranial tumors by flow cytometry (n = 5/5/7/9). One of two representative experiments is shown. (E) Analysis of intracellular IFN-γ
staining in intracranial tumors isolated from Brefeldin A-treated mice (n = 7). Percentage of IFN-γ+ cells within respective immune cell populations (Upper) and
within total cell population (Lower) is shown. Data from two independent experiments were pooled for analysis. Significant differences in D and E, Lower were
determined by ANOVA with a post hoc test, and in E, Upper with Mann–Whitney U Test (one-tailed, *P ≤ 0.05); ***P ≤ 0.001; ****P ≤ 0.0001. Detailed ANOVA
parameters are provided in Table S1.
8 of 10 | www.pnas.org/cgi/doi/10.1073/pnas.1714089115 Taggart et al.
(21%) in drug-treatment naïve patients (15). Thus, by including
extracranial tumor, we achieved an important improvement in
simulating human disease and clinical responses to PD-1 and
CTLA-4 blockade in the brain, and thus our model is expected
to significantly advance preclinical studies on immunotherapy
in BrM.
In terms of adaptive immune responses, the brain is markedly
different from other major sites of metastasis, such as the skin,
lungs, and bones (26). While antigens from these other sites are
efficiently transported to the peripheral lymphoid organs where
T cell priming/activation occurs, a body of literature shows that
antigens located within the brain are less accessible and trans-
ported to lymph nodes at a different location (e.g., cervical
lymph nodes) or presented in a different way (20–23). In line
with this notion, our study reveals that successful targeting of
melanoma BrM with anti–PD-1/anti–CTLA-4 antibodies relies
on: (i) tumor antigens present at extracranial locations and (ii)
release of CD8+ T cells from ICI and their activation occurring
outside the brain. Notably, release of T cells from ICI and their
subsequent increased proliferation following anti–CTLA-4 and
anti–PD-1 therapy is mainly observed within secondary lymphoid
organs and within the tumor microenvironment, respectively
(14). Accordingly, increase in proliferation of intratumoral CD8+
T cells occurs in subcutaneous B16 melanoma tumors following
PD-1 blockade alone or in combination with anti–CTLA-4 or
radiotherapy (34–36). However, in contrast to extracranial sites,
the blood–brain barrier limits access of therapeutic antibodies
into brain tumors, which may preclude anti–PD-1–induced re-
lease of T cells from proliferation block once they have entered
the brain tumor microenvironment. Indeed, in our study, anti–
PD-1/anti–CTLA-4 combination failed to increase the proportion
of proliferative CD8+ T cells and their expression of activation
markers within intracranial tumors. This provides strong evidence
that the release of CD8+ T cells from ICI occurred mainly outside
the brain, and that intracranial anti–PD-1/anti–CTLA-4 activity
relies on the subsequent recruitment of these extracranially acti-
vated CD8+ T cells to intracranial tumors.
Our data suggest that enhanced CD8+ T cell trafficking to in-
tracranial tumors following anti–PD-1/anti–CTLA-4 therapy in
the context of extracranial disease may be enhanced through the
up-regulation of VCAM-1 and ICAM-1 on tumor blood vessels.
IFN-γ was identified as one of the potential factors involved in the
up-regulation of these vascular receptors. NK cells and microglia/
macrophages were the main source of anti–PD-1/anti–CTLA-4–
induced IFN-γ up-regulation. This finding may explain why in-
tracranial anti–PD-1/anti–CTLA-4 efficacy required NK cells and
correlated with intratumoral increase in macrophages. Notably,
the latter may have been recruited to intracranial tumors through
colony stimulating factor 1 (CSF-1), a potent microglia/macro-
phages chemoattractant (37), which—in our study—was found to
be up-regulated 2.8-fold following anti–PD-1/anti–CTLA-4 ther-
apy in the presence of extracranial tumor. Several studies reported
IFN-γ increase in tumors following ICI treatment, although this
has not yet been connected to the up-regulation of vascular T cell
homing determinants or enhanced T cell trafficking (34, 36, 38).
Nevertheless, IFN-γ–dependent up-regulation of ICAM-1 on
choroid plexus epithelial cells in the brain has been recently shown
to increase T cell infiltration into the brain in models of spinal
cord injury and Alzheimer’s disease (39, 40).
More than half of patients with metastatic melanoma develop
BrM and, with ICI becoming the frontline therapy for metastatic
disease, it is critical to understand how ICI can be optimized in
the brain. Because the intracranial anti–PD-1/anti–CTLA-4 effi-
cacy seemed to rely on the recruitment of activated CD8+ T cells
from outside the brain, strategies aimed at enhancing T cell
homing—for example, through adoptive T cell therapy using
T cells with enhanced BrM-homing characteristics—have a strong
potential to improve the efficacy of ICI in the brain. Moreover, our
findings on the critical role of extracranial disease for intracranial
anti–PD-1/anti–CTLA-4 efficacy are of relevance to the optimi-
zation of ICI for primary nonmetastatic brain cancers, in particular
glioma. Notably, in contrast to clinical evidence for anti–PD-1 ac-
tivity in melanoma BrM (12, 13), a recent phase III clinical trial of
nivolumab in glioma was negative (https://news.bms.com/press-
release/bmy/bristol-myers-squibb-announces-results-checkmate-
143-phase-3-study-opdivo-nivoluma). Our data suggest that the
combination of ICI with strategies that boost the peripheral
antigen-specific T cell activation, such as cancer vaccines, may
also improve anti–PD-1/anti–CTLA-4 efficacy in metastatic and
nonmetastatic brain cancers.
Materials and Methods
In Vivo Model of Brain Metastases. All procedures were approved by the
University of Leeds Animal Welfare and Ethical Review Committee and
performed under the approved United Kingdom Home Office project license
in line with the Animal (Scientific Procedures) Act 1986 and in accordance
with the United Kingdom National Cancer Research Institute Guidelines for
the welfare of animals (41).
Six- to 8-wk-old female C57BL/6J or B6N-Tyrc-Brd/BrdCrCrl (B6 Albino) mice
were purchased from Charles River Laboratories, UK. B16 F1, B16/OVA, or Ret
melanoma cells (please refer to SI Materials and Methods for cell line details)
were injected subcutaneously on the flank to generate extracranial tumors
(2 × 105 B16 and B16/OVA cells; 1 × 105 Ret cells). To generate intracranial
tumors, cancer cells (1 × 105 B16/Fluc and B16/OVA/Fluc cells; 1 × 103 Ret/Fluc
cells) were stereotactically injected into the striatum (2-mm right from the
midline, 2-mm anterior from bregma, 3-mm deep). Before treatment, mice
used in experiments with B16 and B16/OVA models were randomized into
groups based on the intracranial bioluminescence signals ensuring equal
distribution of tumor burden across groups. Mice used in experiments with
the Ret melanoma model were randomized into groups so as to ensure an
equal proportion of mice from different litters per group (randomization
based on the bioluminescence signal intensity was not possible at early time
points due to the low number of implanted cells in this model). Anti–PD-1
(RMP1-14), anti–CTLA-4 (9D9), and IgG control (MPC11) were purchased
from Bio-X-Cell and administered intraperitoneally at 200 μg per mouse,
as indicated.
Experimental group sizes were determined with power analysis (power =
80%, significance level = 5%, difference to be detected between groups =
50%) using the mean values and SDs from our pilot studies. All animals were
included in the survival analysis and tumor growth analysis. In cases where
tumors were too small to obtain sufficient material for FACS analysis, the
animals were excluded from this analysis. All outliers were included in the
analysis. The study was not blinded.
Quantification of extracranial tumor growth was performed by caliper
measurement. Quantification of intracranial tumor growth was performed
via noninvasive bioluminescence imaging using IVIS Spectrum and Living
Image software (PerkinElmer).
Immune cell depletion was achieved through intraperitoneal adminis-
tration of anti-CD8α (YTS.4; Bio-X-Cell), anti-CD4 (GK1.5; Bio-X-Cell), or
antiasialo-GM1 that depletes NK cells (polyclonal rabbit IgG; Cedarlane) at
100 μg per mouse every 4 d. For detection of IFN-γ and TNF-α by flow
cytometry, mice received 250 μg Brefeldin A (Sigma) intravenously 6 h be-
fore tissue harvesting. Adoptive T cell transfer experiments are described in
SI Materials and Methods.
Immunofluorescence. Immunofluorescence was performed as previously de-
scribed (25). Details are provided in SI Materials and Methods.
Flow Cytometry. Mice were perfused with saline. Tumors were mechanically
disrupted and enzymatically dissociated (25). The blood (collected from tail
vein) and splenocytes were treated with ammonium-chloride-potassium
buffer to lyse red blood cells. Samples were blocked with 10% rat serum
and FcR blocking reagent (Miltenyi) before surface antigen staining. FoxP3/
Transcription Factor Staining Buffer Set (eBioscience) was used for
intracellular staining of nuclear antigens following the manufacturer’s instruc-
tions. Intracellular fixation buffer and Permeabilization buffer (eBioscience)
were used for staining of cytoplasmic antigens following manufacturer’s in-
structions. Cells were analyzed on BD LSRII Flow Cytometry Analyzer (Life
Technologies). Data were quantified using FACSDiva software. The gates were
set based on appropriate isotype controls. Antibody details are provided in
SI Materials and Methods.

























RNAseq and Gene-Expression Analysis. Details of RNAseq and gene-expression
analysis are provided under SI Materials and Methods.
Statistical Analysis. Statistical analysis was carried out using Graph Pad Prism
v7 (Graph Pad Software). Statistical tests used were ANOVA with a post hoc
test for multiple comparisons (Tukey’s multiple comparisons test), Mann–
Whitney test, and Mann–Whitney U test, as specified in figure legends. All
tests except the Mann–Whitney U test were two-tailed statistical tests.
Statistical significance in survival experiments was determined with log-
rank test. Error bars represent SEM, except in Fig. 6E, Upper, where the
bars represent SDs. The number of biological replicates for each experi-
ment is stated in figure legends. Each experiment was performed two to
four times, as specified. Data from repeat experiments were combined as
indicated in the figure legends.
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